|
|
| (3 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Cilostazol#Adult Indications and Dosage]] |
| {{Cilostazol}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
| | |
| ==Dosage And Administration==
| |
| | |
| The recommended dosage of PLETAL is 100 mg b.i.d. taken at least half an hour before or two hours after breakfast and dinner. A dose of 50 mg b.i.d. should be considered during coadministration of such inhibitors of CYP3A4 as [[ketoconazole]], [[itraconazole]], [[erythromycin]] and [[diltiazem]], and during coadministration of such inhibitors of CYP2C19 as [[omeprazole]].
| |
| | |
| Patients may respond as early as 2 to 4 weeks after the initiation of therapy, but treatment for up to 12 weeks may be needed before a beneficial effect is experienced.
| |
| | |
| ====Discontinuation of Therapy====
| |
| | |
| The available data suggest that the dosage of PLETAL can be reduced or discontinued without rebound (i.e., platelet hyperaggregability).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PLETAL (CILOSTAZOL) TABLET [OTSUKA AMERICA PHARMACEUTICAL, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24d75b58-bafb-4440-b8d7-4f4079c08b0b | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Drugs]]
| |